Oncoscience | A murine model for human early/

“As anticipated, we found that the onset of leukemia was significantly accelerated in Idh2R140Q/NHD13 double transgenic mice […]”

BUFFALO, NY- January 23, 2023 – A new research perspective was published in Oncoscience (Volume 9) on October 24, 2022, entitled, “A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL).”

In this research perspective, researchers Vijay Negi and Peter D. Aplan from the National Institutes of Health’s National Cancer Institute discussed early/immature T cell precursor acute lymphoblastic leukemia (EITP ALL). EITP ALL represents a subset of human leukemias distinct from other T-ALL, and associated with poor prognosis. Clinical studies have identified chromosomal translocations involving the NUP98 gene and point mutations of IDH genes as recurrent mutations in patients with EITP-ALL. 

“In a recent study using genetically engineered mice, we demonstrated that cooperation of an Idh2R140Q mutation with a NUP98-HOXD13 (NHD13) fusion gene resulted in EITP-ALL.”

Highlights of this double transgenic mouse model included the similarity of the immunophenotypic, mutational and gene expression landscape with human EITP-ALL. Additional studies showed that the Idh2R140Q/NHD13 EITP-ALL are sensitive to selective mutant IDH2 inhibitors in vitro, leading to the possibility that these mice can serve as a useful model for the study of EITP ALL development and therapy.

“We predict that the Idh2R140Q/NHD13 mouse model will serve as an excellent tool to study EITP biology and identify therapies for patients with EITP leukemia.”


DOI: https://doi.org/10.18632/oncoscience.567 

Correspondence to: Peter D. Aplan Email: aplanp@mail.nih.gov 

Keywords: early thymocyte precursor (ETP), leukemia, IDH2, NUP98, NHD13

About Oncoscience

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:


For media inquiries, please contact media@impactjournals.com.


Oncoscience Journal Office

6666 East Quaker Str., Suite 1D

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 4


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *